PURPOSE OF REVIEW: In immunocompromised hosts, invasive fungal infections are common and fatal. In the past decade, the antifungal armamentarium against invasive mycoses has expanded greatly. The purpose of the present report is to review the most recent literature addressing the use of antifungal agents in children. RECENT FINDINGS: Most studies evaluating the safety and efficacy of antifungal agents are limited to adults. However, important progress has been made in describing the pharmacokinetics and safety of newer antifungal agents in children, including the echinocandins. SUMMARY: Dosage guidelines for newer antifungal agents are currently based on adult and limited pediatric data. Because important developmental pharmacology changes occur throughout childhood impacting the pharmacokinetics of these agents, antifungal studies specifically designed for children are necessary.
PURPOSE OF REVIEW: In immunocompromised hosts, invasive fungal infections are common and fatal. In the past decade, the antifungal armamentarium against invasive mycoses has expanded greatly. The purpose of the present report is to review the most recent literature addressing the use of antifungal agents in children. RECENT FINDINGS: Most studies evaluating the safety and efficacy of antifungal agents are limited to adults. However, important progress has been made in describing the pharmacokinetics and safety of newer antifungal agents in children, including the echinocandins. SUMMARY: Dosage guidelines for newer antifungal agents are currently based on adult and limited pediatric data. Because important developmental pharmacology changes occur throughout childhood impacting the pharmacokinetics of these agents, antifungal studies specifically designed for children are necessary.
Authors: M A Pfaller; D J Diekema; L Boyken; S A Messer; S Tendolkar; R J Hollis; B P Goldstein Journal: Antimicrob Agents Chemother Date: 2005-11 Impact factor: 5.191
Authors: Thomas J Walsh; Peter C Adamson; Nita L Seibel; Patricia M Flynn; Michael N Neely; Cindy Schwartz; Aziza Shad; Sheldon L Kaplan; Maureen M Roden; Julie A Stone; Alisha Miller; Susan K Bradshaw; Susan X Li; Carole A Sable; Nicholas A Kartsonis Journal: Antimicrob Agents Chemother Date: 2005-11 Impact factor: 5.191
Authors: Nita L Seibel; Cindy Schwartz; Antonio Arrieta; Patricia Flynn; Aziza Shad; Edith Albano; James Keirns; Wendi M Lau; David P Facklam; Donald N Buell; Thomas J Walsh Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191
Authors: Brahm H Segal; Lisa A Barnhart; Victoria L Anderson; Thomas J Walsh; Harry L Malech; Steven M Holland Journal: Clin Infect Dis Date: 2005-04-29 Impact factor: 9.079
Authors: Carla M Odio; Roberto Araya; Luis E Pinto; Carlos E Castro; Sergio Vasquez; Braulio Alfaro; Alberto Sàenz; Marco L Herrera; Thomas J Walsh Journal: Pediatr Infect Dis J Date: 2004-12 Impact factor: 2.129
Authors: R Courtney; A Sansone; W Smith; T Marbury; P Statkevich; M Martinho; M Laughlin; S Swan Journal: J Clin Pharmacol Date: 2005-02 Impact factor: 3.126
Authors: V Petraitis; R Petraitiene; A H Groll; A Bell; D P Callender; T Sein; R L Schaufele; C L McMillian; J Bacher; T J Walsh Journal: Antimicrob Agents Chemother Date: 1998-11 Impact factor: 5.191
Authors: I Spriet; K Cosaert; M Renard; A Uyttebroeck; I Meyts; M Proesmans; G Meyfroidt; J de Hoon; R Verbesselt; L Willems Journal: Eur J Clin Microbiol Infect Dis Date: 2010-10-21 Impact factor: 3.267
Authors: Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin Journal: Clin Pharmacokinet Date: 2014-05 Impact factor: 6.447
Authors: M Döring; M Eikemeier; K M Cabanillas Stanchi; U Hartmann; M Ebinger; C-P Schwarze; A Schulz; R Handgretinger; I Müller Journal: Eur J Clin Microbiol Infect Dis Date: 2015-02-14 Impact factor: 3.267